A micro-sized vaccine based on recombinant Lactiplantibacillus plantarum fights against SARS-CoV-2 infection via intranasal immunization

文献类型： 外文期刊

第一作者： Li, Letian

作者： Li, Letian;Hao, Jiayi;Jiang, Yuhang;Hao, Pengfei;Gao, Yuwei;Chen, Jing;Zhang, Guoqing;Jin, Ningyi;Li, Chang;Wang, Maopeng

作者机构：

关键词： COVID-19; Mucosal vaccines; Lactiplantibacillus plantarum; Microparticle; Intranasal administration; Viral challenge; Mice; Lung targeting delivery system

期刊名称：ACTA PHARMACEUTICA SINICA B （ 影响因子：14.5； 五年影响因子：13.2 ）

ISSN： 2211-3835

年卷期： 2023 年 13 卷 7 期

页码：

收录情况： SCI

摘要： COVID-19 has globally spread to burden the medical system. Even with a massive vaccina-tion, a mucosal vaccine offering more comprehensive and convenient protection is imminent. Here, a micro-sized vaccine based on recombinant Lactiplantibacillus plantarum (rLP) displaying spike or receptor-binding domain (RBD) was characterized as microparticles, and its safety and protective effects against SARS-CoV-2 were evaluated. We found a 66.7% mortality reduction and 100% protection with rLP against SARS-CoV-2 in a mouse model. The histological analysis showed decreased hemorrhage symptoms and increased leukocyte infiltration in the lung. Especially, rLP:RBD significantly decreased pulmonary viral loads. For the first time, our study provides a L. plantarum-vectored vaccine to prevent COVID-19 progress and transmission via intranasal vaccination.& COPY; 2023 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

分类号：

  • 相关文献
作者其他论文 更多>>

微信小程序